本帖最后由 老马 于 2013-3-13 13:43 编辑 ' Q7 j- E5 }9 Y0 p. D" c% ^: k
/ U7 l1 n+ U) c健择（吉西他滨）+顺铂+阿瓦斯汀
/ X8 y' B! I4 i6 O5 k2 D Gemzar +Cisplatin + Avastin7 u1 ~/ T* ?2 ^* q$ h
http://annonc.oxfordjournals.org/content/21/9/1804.full' E _, h7 i2 H$ n
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 U+ E) t: Q. U) Y7 `! `- i- `% u
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: h2 L% Z+ v5 F- l& Z2 CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 5 z2 O7 s8 c. \9 i
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 818)
* v, K' v: S y0 h% ?7 A4 b3 h8 k/ t华为网盘附件：) H3 ?: |$ c# Y3 M) m# g6 ~$ W
【华为网盘】ava.JPG
! V J& W: j4 U( T* K; Y1 K3 y |
显身卡
